Tectorigenin suppresses the viability of gastric cancer cells in vivo and in vitro

Main Article Content

Wenchong Song
Weiwei Lv
Ning Bi
Guanglin Wang

Keywords

Apoptosis, cell cycle, gastric cancer, PI3K/Akt pathway, Tectorigenin (Tec)

Abstract

Gastric cancer is currently the 4th most common malignant tumor with a poor prognosis in 2022. New and effective drugs are needed to combat this disease to treat advanced gastric cancer. Tectorigenin (Tec) has a series of pharmacological activities, such as anti-inflammatory and anticancer. However, the effect of Tec on the progression of gastric cancer is unclear. In this study, we investigated the role of Tec in regulating cell viability, cell cycle, and tumor growth of gastric cancer. To detect the role of Tec in the progression of gastric cancer in vitro and in mice, we performed several in vitro assays such as MTT, colony formation, wound closure, transwell, Immunoblot assays, and in vivo tumor growth assays. Our data confirmed that Tec restrained the viability of gastric cancer cells at concentrations of 100, 200, and 300 μM. It also denied the motility of gastric cancer cells. Tec treatment also induced the cell cycle arrest of gastric cancer cells. Mechanically, Tec could suppress the activation of the PI3K/Akt pathway and stop gastric cancer progression. We, therefore, thought Tec could serve as a drug for treating gastric cancer.

Abstract 192 | PDF Downloads 162 HTML Downloads 3 XML Downloads 14

References

Akbari, A., Ashtari, S., Tabaiean, S. P., Mehrdad-Majd, H., Farsi, F., Shojaee, S., & Agah, S. (2022). Overview of epidemiological characteristics, clinical features, and risk factors of gastric cancer in Asia-Pacific region. Asia-Pacific Journal of Clinical Oncology. 18(6): 493–505. 10.1111/ajco.13654

Camilloni, A., Nati, G., Maggiolini, P., Romanelli, A. and Latina, R., 2021. Chronic non-cancer pain in primary care: an Italian cross-sectional study. Signa Vitae. 7: 54–62.

Chen, W., He, Q., Liu, J., Li, N., Xiao, K. and Chen, H., 2023. PLAGL2 promotes Snail expression and gastric cancer progression via UCA1/miR-145-5p/YTHDF1 axis. Carcinogenesis. 44(4): 328–340. 10.1093/carcin/bgad016

Chen, Y., Song, W., Peng, Z. H., Ge, B. Y. and Han, F. M., 2008. Identification of metabolites of tectoridin in-vivo and in-vitro by liquid chromatography-tandem mass spectrometry. Journal of Pharmacy and Pharmacology. 60: 709–716. 10.1211/jpp.60.6.0005

Hu, J., Wang, Z., Wang, X. and Xie, S., 2023. Side-effects of hyperthermic intraperitoneal chemotherapy in patients with gastrointestinal cancers. Peer J. 11: e15277. 10.7717/peerj.15277

Jiang, C. P., Ding, H., Shi, D. H., Wang, Y. R., Li, E. G. and Wu, J. H., 2012. Pro-apoptotic effects of tectorigenin on human hepatocellular carcinoma HepG2 cells. World Journal of Gastroenterology. 18: 1753–1764. 10.3748/wjg.v18.i15.1753

Lan, W. H., Lin, T. Y., Yeh, J. A., Feng, C. L., Hsu, J. T., Lin, H. J., Kuo, C. J. and Lai, C. H., 2022. Mechanism underlying metformin action and its potential to reduce gastric cancer risk. International Journal of Molecular Sciences. 23. 10.3390/ijms232214163

Li, J., Yan, W., Ren, F. and Sang, H., 2023. Tectorigenin inhibits inflammation in keratinocytes by inhibition of NLRP3 inflammasome regulated by the TLR4/NF-kappaB pathway. Allergologia et Immunopathologia. 51: 82–89. 10.15586/aei.v51i2.780

Li, J., Yang, J., Zhu, B., Fan, J., Hu, Q. and Wang, L., 2022. Tectorigenin protects against unilateral ureteral obstruction by inhibiting Smad3-mediated ferroptosis and fibrosis. Phytotherapy Research. 36: 475–487. 10.1002/ptr.7353

Li, Q. Y., Chen, L., Yan, M. M., Shi, X. J. and Zhong, M. K., 2015. Tectorigenin regulates adipogenic differentiation and adipocytokines secretion via PPARgamma and IKK/NF-kappaB signaling. Pharmaceutical Biology. 53: 1567–1575. 10.3109/13880209.2014.993038

Li, Y., Sun, Q., Jiang, M., Li, S., Zhang, J., Xu, Z., Guo, D., Gu, T., Wang, B., Xiao, L., Zhou, T. and Zhuo, W., 2019. KLF9 suppresses gastric cancer cell invasion and metastasis through transcriptional inhibition of MMP28. FASEB Journal. 33: 7915–7928. 10.1096/fj.201802531R

Liu, S., Wang, J., Zhang, J., Wang, T., Zhou, Y., Lv, Q., Hu, N., Shen, X. and Deng, X., 2019. Tectorigenin reduces type IV pilus--dependent cell adherence in Clostridium perfringens. FEMS Microbiology Letters. 366(10): fnz112. 10.1093/femsle/fnz112

Ooki, A. and Yamaguchi, K., 2022. The dawn of precision medicine in diffuse-type gastric cancer. Therapeutic Advances in Medical Oncology. 14: 17588359221083049. 10.1177/17588359221083049

Qian, X., Xiao, Q. and Li, Z., 2021. Tectorigenin regulates migration, invasion, and apoptosis in dexamethasone-induced human airway epithelial cells through up-regulating miR-222-3p. Drug Development Research. 82: 959–968. 10.1002/ddr.21795

Shang, X., Zhao, Y., Xu, T., Ma, Q. and Su, Z., 2023. Differential value of PGI, PGII and G-17 in chronic atrophic gastritis and early gastric cancer. Minerva Pediatrics. (Torino). 10.23736/S2724-5276.23.07261-0

Sharma, N. and Sageena, G., 2022. Dietary factors associated with gastric cancer-a review. Translational Medicine Communications. 7: 1–11.

Suh, K. J., Ryu, M. H., Zang, D. Y., Bae, W. K., Lee, H. S., Oh, H. J., Kang, M., Kim, J. W., Kim, B. J., Mortimer, P. G. S., Kim, H. J. and Lee, K. W., 2023. AZD8186 in combination with paclitaxel in patients with advanced gastric cancer: results from a phase Ib/II study (KCSG ST18-20). Oncologist. 28(9): e823–e834. 10.1093/oncolo/oyad059

Wang, Y., Jing, W., Qu, W., Liu, Z., Zhang, D., Qi, X. and Liu, L., 2020. Tectorigenin inhibits inflammation and pulmonary fibrosis in allergic asthma model of ovalbumin-sensitized guinea pigs. The Journal of Pharmacy and Pharmacology. 72: 956–968. 10.1111/jphp.13271

Xiang, J., Yang, G., Ma, C., Wei, L., Wu, H., Zhang, W., Tao, X., Jiang, L., Liang, Z., Kang, L. and Yang, S., 2021. Tectorigenin alleviates intrahepatic cholestasis by inhibiting hepatic inflammation and bile accumulation via activation of PPARgamma. British Journal of Pharmacology. 178: 2443–2460. 10.1111/bph.15429

Yamamoto, K., Omori, T., Kurokawa, Y., Takeno, A., Akamaru, Y., Demura, K., Okada, K., Kishi, K., Saito, T., Takahashi, T., Eguchi, H. and Doki, Y., 2023. Laparoscopic gastrectomy for advanced gastric cancer. The American Surgeon: 31348221114042. 10.1177/00031348221114042

Yang, S., Ma, C., Wu, H., Zhang, H., Yuan, F., Yang, G., Yang, Q., Jia, L., Liang, Z. and Kang, L., 2020. Tectorigenin attenuates diabetic nephropathy by improving vascular endothelium dysfunction through activating AdipoR1/2 pathway. Pharmacological Research 153: 104678. 10.1016/j.phrs.2020.104678

Yao, L., Yang, M., Zhang, J., Wang, F., Liu, Q., Xie, X., Liu, Z., Guo, Q., Su, H., Zhai, J., He, J., Xue, S. and Qiu, Z., 2021. Tectorigenin attenuates the OGD/R-induced HT-22 cell damage through regulation of the PI3K/AKT and the PPARgamma/NF-kappaB pathways. Human and Experimental Toxicology. 40: 1320–1331. 10.1177/0960327121993213

Yeh, L. T., Hsu, L. S., Chung, Y. H. and Chen, C. J., 2020. Tectorigenin inhibits glioblastoma proliferation by G0/G1 cell cycle arrest. medicina (Kaunas). 56(12): 681. 10.3390/medicina56120681

Zhao, X. Y., Liu, X., Li, W. H., Qiu, L. X., Huang, M. Z., Wang, C. C., Chen, Z. Y., Zhang, W., Feng, W. J., Guo, W. J. and Zhu, X., 2022. Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer. Frontiers in Oncology. 12: 911160. 10.3389/fonc.2022.911160